Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 9/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 9/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 9/20 | 0.48 |
| ▸ | HTR2A | P28223 | 7/20 | 0.48 |
| ▸ | HTR2C | P28335 | 7/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340773 | 1.00 | SMARCA2 (0.48) | SMARCA2SMARCA4PBRM1HTR2AHTR2C | |
| SCHEMBL23580329 | 0.74 | GAA (0.42) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL26653859 | 0.73 | PBRM1 (0.55) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL23580952 | 0.73 | HTR2C (0.50) | HTR2AHTR2C | |
| SCHEMBL26653819 | 0.68 | PBRM1 (0.43) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL26888566 | 0.68 | SMARCA2 (0.54) | SMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL26653892 | 0.68 | SMARCA2 (0.43) | SMARCA2SMARCA4PBRM1NR1I2BRD4 | |
| SCHEMBL31570178 | 0.68 | SMARCA2 (0.57) | SMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL26685303 | 0.68 | SMARCA2 (0.57) | SMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL26888980 | 0.68 | SMARCA2 (0.57) | SMARCA2SMARCA4PBRM1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | SMARCA2 6/4885SMARCA4 7/4885PBRM1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.